nach oben

Erschienen in:

01.07.2013 | Original Paper

p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway

verfasst von: Guihua Wang, Cheng Chen, Rui Yang, Xiaonian Cao, Senyan Lai, Xuelai Luo, Yongdong Feng, Xianmin Xia, Jianping Gong, Junbo Hu

Erschienen in: Angiogenesis | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Vascular growth factor (VEGF) is an important mediator of angiogenesis. PI3K plays essential roles in angiogenesis; however, the mechanisms and specific functions of individual isoforms of PI3K members in tumor angiogenesis regulation are still not fully understood. In this study, we evaluate the role of p55PIK, a PI3K regulatory subunit encoded by PIK3R3 gene, in tumor angiogenesis. We reported that overexpression of p55PIK in cancer cells up-regulated HIF-1α expression and increased VEGF expression. Furthermore, overexpression of p55PIK increased tumor angiogenesis in vivo and in vitro. Moreover, data indicated enhanced HIF-1α expression by p55PIK-PI3K depended on its ability to activate NF-кB signaling pathways, especially to increase the phosphorylation of p65 subunits of NF-κB. Our study suggested that p55PIK-PI3K was essential in regulating cancer cell-mediated angiogenesis and contributed to tumor growth and that the p55PIK provides a potential and specific target for new anti-angiogenesis drug development.

Nur mit Berechtigung zugänglich

Anderson DH (2010) p85 Plays a critical role in controlling flux through the PI3K/PTEN signaling axis through dual regulation of both p110 (PI3K) and PTEN. Cell Cycle 9:2055–2056

Berenjeno IM, Vanhaesebroeck B (2009) PI3K regulatory subunits lose control in cancer. Cancer Cell 16:449–450PubMedCrossRef

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410PubMedCrossRef

Bikfalvi A (2006) Angiogenesis: health and disease. Ann Oncol 17(Suppl 10):x65–x70PubMedCrossRef

Bunney TD, Katan M (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10:342–352PubMedCrossRef

Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660PubMedCrossRef

Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222–243PubMedCrossRef

Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083PubMedCrossRef

Dayan F, Bilton RL, Laferriere J et al (2009) Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway. J Cell Physiol 218:167–174PubMedCrossRef

10.

Du J, Xu R, Hu Z et al (2011) PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1alpha expression in MCF-7 breast cancer cells. PLoS One 6:e25213PubMedCrossRef

11.

Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef

12.

Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364:656–665PubMedCrossRef

13.

Fang J, Ding M, Yang L et al (2007) PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 19:2487–2497PubMedCrossRef

14.

Foukas LC, Berenjeno IM, Gray A et al (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 107:11381–11386PubMedCrossRef

15.

Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6:507–518PubMedCrossRef

16.

Hamada K, Sasaki T, Koni PA et al (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19:2054–2065PubMedCrossRef

17.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRef

18.

Hu J, Liu S, Wang J et al (2005) Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells. Int J Oncol 26:1321–1327PubMed

19.

Hu J, Xia X, Cheng A et al (2008) A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther 7:3719–3728PubMedCrossRef

20.

Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374–380PubMedCrossRef

21.

Jia S, Liu Z, Zhang S et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776–779PubMed

22.

Jiang BH, Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19–65PubMedCrossRef

23.

Karar J, Maity A (2011) PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4:51PubMedCrossRef

24.

Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039–2049PubMedCrossRef

25.

Kloo B, Nagel D, Pfeifer M et al (2011) Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 108:272–277PubMedCrossRef

26.

Lawrence T, Bebien M, Liu GY et al (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434:1138–1143PubMedCrossRef

27.

Marone R, Cmiljanovic V, Giese B et al (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784:159–185PubMedCrossRef

28.

Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94:8104–8109PubMedCrossRef

29.

Menakuru SR, Brown NJ, Staton CA et al (2008) Angiogenesis in pre-malignant conditions. Br J Cancer 99:1961–1966PubMedCrossRef

30.

Mitchell DC, Bryan BA (2010) Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. J Cell Biochem 111:543–553PubMedCrossRef

31.

Mylonis I, Chachami G, Paraskeva E et al (2008) Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. J Biol Chem 283:27620–27627PubMedCrossRef

32.

Okumura N, Yoshida H, Kitagishi Y et al (2012) PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Adv Hematol 2012:843085PubMed

33.

Pufe T, Lemke A, Kurz B et al (2004) Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 164:185–192PubMedCrossRef

34.

Rhodes DR, Yu J, Shanker K et al (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101:9309–9314PubMedCrossRef

35.

Rhodes DR, Yu J, Shanker K et al (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1–6PubMed

36.

Sakurai H, Chiba H, Miyoshi H et al (1999) IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274:30353–30356PubMedCrossRef

37.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 3:1101–1108PubMedCrossRef

38.

Skrzypczak M, Goryca K, Rubel T et al (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. Plos One 5:e13091

39.

Tian T, Nan KJ, Wang SH et al (2010) PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 31:1211–1219PubMedCrossRef

40.

Tsuzuki Y, Fukumura D, Oosthuyse B et al (2000) Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha–> hypoxia response element–> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 60:6248–6252PubMed

41.

Van Uden P, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412:477–484PubMedCrossRef

42.

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Bio 11:329–341CrossRef

43.

Wang G, Deng Y, Cao X et al (2012) Blocking p55PIK Signaling inhibits proliferation and induces differentiation of leukemia cells. Cell Death Differ 19:1870–1879

44.

Wee S, Wiederschain D, Maira SM et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105:13057–13062PubMedCrossRef

45.

Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef

46.

Winder T, Lenz HJ (2010) Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 138:2163–2176PubMedCrossRef

47.

Xia X, Cheng A, Akinmade D et al (2003) The N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol Cell Biol 23:1717–1725PubMedCrossRef

48.

Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510PubMedCrossRef

49.

Zhang L, Huang J, Yang N et al (2007) Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13:5314–5321PubMedCrossRef

50.

Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486–5496PubMedCrossRef

Titel: p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway
verfasst von: Guihua Wang
Cheng Chen
Rui Yang
Xiaonian Cao
Senyan Lai
Xuelai Luo
Yongdong Feng
Xianmin Xia
Jianping Gong
Junbo Hu
Publikationsdatum: 01.07.2013
Verlag: Springer Netherlands
Erschienen in: Angiogenesis / Ausgabe 3/2013
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-013-9336-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Mechanistic study of the proangiogenic effect of osteoprotegerin

Non-invasive dynamic near-infrared imaging and quantification of vascular leakage in vivo

Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells

CD44 regulates vascular endothelial barrier integrity via a PECAM-1 dependent mechanism

TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis